Anti-TNF drugs show potential in Alzheimer's

5 December 2019

brain_alzheimer_credit_depositphotos_large

Privately-held US biotech Tetra Therapeutics has presented data showing that TNF-blocking agents reduce the risk of Alzheimer’s disease in patients with rheumatoid arthritis or psoriasis.

The CNS specialist presented the data from a retrospective population-based study of 56 million patients at the Alzheimer’s Disease Meeting being held in San Diego, California.

Inflammatory disease in the body is shown to increase the risk of Alzheimer’s, and that risk can be reduced in these patients by treatment with a TNF blocking drug, the findings suggest.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK